MCMaría Cámara-Quílez

María Cámara-Quílez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


María Cámara-Quílez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Aida Barreiro-Alonso

    Grupo EXPRELA, CICA - Centro Interdisciplinar de Química e Biología, Departamento de Biología, Facultade de Ciencias, Universidade da Coruña, Campus de Elviña15071 A Coruña, España

    3 shared publications
  • Maria Esperanza Cerdán

    Grupo EXPRELA, CICA - Centro Interdisciplinar de Química e Biología, Departamento de Biología, Facultade de Ciencias, Universidade da Coruña, Campus de Elviña15071 A Coruña, España

    3 shared publications
  • Mónica Lamas-Maceiras

    Grupo EXPRELA, CICA - Centro Interdisciplinar de Química e Biología, Departamento de Biología, Facultade de Ciencias, Universidade da Coruña, Campus de Elviña15071 A Coruña, España

    3 shared publications
  • Ángel Vizoso-Vázquez

    Grupo EXPRELA, CICA - Centro Interdisciplinar de Química e Biología, Departamento de Biología, Facultade de Ciencias, Universidade da Coruña, Campus de Elviña15071 A Coruña, España

    3 shared publications
  • Esther Rodríguez-Belmonte

    EXPRELA Group, Centro de Investigacións Científicas Avanzadas (CICA), Departamento de Bioloxía, Facultade de Ciencias, INIBIC-Universidade da Coruña, Campus de A Coruña, 15071 A Coruña, Spain

    2 shared publications
  • María Quindós-Varela

    Medical Oncology Department, Complexo Hospitalario Universitario de A Coruña. Biomedical Research Institute (INIBIC), A Coruña, Spain

    2 shared publications

Latest Publications

  • Open Access

    Thanksgiving to Yeast, the HMGB Proteins History from Yeast to Cancer

    by Mónica Lamas-Maceiras, Ángel Vizoso-Vázquez, Aida Barreiro-Alonso, María Cámara-Quílez, María Esperanza Cerdán

    Yeasts have been a part of human life since ancient times in the fermentation of many natural products used for food. In addition, in the 20th century, they became powerful tools to elucidate the functions of eukaryotic cells as soon as the techniques of molecular biology developed. Our molecular understandings of metabolism, cellular transport, DNA repair, gene expression and regulation, and the cell division cycle have all been obtained through biochemistry and genetic analysis using different yeasts. In this review, we summarize the role that yeasts have had in biological discoveries, the use of yeasts as biological tools, as well as past and on-going research projects on HMGB proteins along the way from yeast to cancer.


  • Open Access

    The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response

    by María Cámara-Quílez, Aida Barreiro-Alonso, Ángel Vizoso-Vázquez, Esther Rodríguez-Belmonte, María Quindós-Varela, Mónica Lamas-Maceiras, María Esperanza Cerdán

    High mobility group box B (HMGB) proteins are overexpressed in different types of cancers such as epithelial ovarian cancers (EOC). We have determined the first interactome of HMGB1 and HMGB2 in epithelial ovarian cancer (the EOC-HMGB interactome). Libraries from the SKOV-3 cell line and a primary transitional cell carcinoma (TCC) ovarian tumor were tested by the Yeast Two Hybrid (Y2H) approach. The interactome reveals proteins that are related to cancer hallmarks and their expression is altered in EOC. Moreover, some of these proteins have been associated to survival and prognosis of patients. The interaction of MIEN1 and NOP53 with HMGB2 has been validated by co-immunoprecipitation in SKOV-3 and PEO1 cell lines. SKOV-3 cells were treated with different anti-tumoral drugs to evaluate changes in HMGB1, HMGB2, MIEN1 and NOP53 gene expression. Results show that combined treatment of paclitaxel and carboplatin induces a stronger down-regulation of these genes in comparison to individual treatments. Individual treatment with paclitaxel or olaparib up-regulates NOP53, which is expressed at lower levels in EOC than in non-cancerous cells. On the other hand, bevacizumab diminishes the expression of HMGB2 and NOP53. This study also shows that silencing of these genes affects cell-viability after drug exposure. HMGB1 silencing causes loss of response to paclitaxel, whereas silencing of HMGB2 slightly increases sensitivity to olaparib. Silencing of either HMGB1 or HMGB2 increases sensitivity to carboplatin. Lastly, a moderate loss of response to bevacizumab is observed when NOP53 is silenced.


  • Open Access

    Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications

    by Aida Barreiro-Alonso, María Cámara-Quílez, Martín Salamini-Montemurri, Mónica Lamas-Maceiras, Ángel Vizoso-Vázquez, Esther Rodríguez-Belmonte, María Quindós-Varela, Olaia Martínez-Iglesias, Angélica Figueroa, María-Esperanza Cerdán

    High mobility group box B (HMGB) proteins are pivotal in the development of cancer. Although the proteomics of prostate cancer (PCa) cells has been reported, the involvement of HMGB proteins and their interactome in PCa is an unexplored field of considerable interest. We describe herein the results of the first HMGB1/HMGB2 interactome approach to PCa. Libraries constructed from the PCa cell line, PC-3, and from patients’ PCa primary tumor have been screened by the yeast 2-hybrid approach (Y2H) using HMGB1 and HMGB2 baits. Functional significance of this PCa HMGB interactome has been validated through expression and prognosis data available on public databases. Copy number alterations (CNA) affecting these newly described HMGB interactome components are more frequent in the most aggressive forms of PCa: those of neuroendocrine origin or castration-resistant PCa. Concordantly, adenocarcinoma PCa samples showing CNA in these genes are also associated with the worse prognosis. These findings open the way to their potential use as discriminatory biomarkers between high and low risk patients. Gene expression of a selected set of these interactome components has been analyzed by qPCR after HMGB1 and HMGB2 silencing. The data show that HMGB1 and HMGB2 control the expression of several of their interactome partners, which might contribute to the orchestrated action of these proteins in PCa